Novo Nordisk’s stock dives as new weight loss drug disappoints in a late-stage trial, which gave a boost to Eli Lilly shares.

U.S. stock futures are pointing lower as investors watch for a potential partial government shutdown; economists expect the ...

Novo Nordisk said on Friday its experimental next-generation obesity drug CagriSema helped patients cut their weight by 22.7% ...

Novo Nordisk's trial for its obesity drug CagriSema resulted in a lower-than-expected weight loss of 22.7%, impacting its market value. Despite these results, Novo remains optimistic about further ...

FedEx Corp shares increased 9% in Friday's premarket session after the package delivery company outlined plans to spin off its FedEx Freight trucking business Eli Lilly s ...

One out of 20 prescriptions written in the U.S. is for a GLP-1 drug. US doctors write billions of prescriptions each year.

As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented ...

The U.S. Food and Drug Administration re-issued a decision first made by the agency in October that a shortage of the ...

Specialty pharmacies and online companies were selling the off-brand copies while there was a shortage of Zepbound and Mounjaro.

Approved in 2022 for type 2 diabetes and in 2023 for chronic weight management along with diet and exercise, tirzepatide is ...

Health-care companies fell amid ongoing concerns about a backlash against the industry. The SPDR Select Sector Health Care exchange-traded fund, which tracks the health-care industry group of the S&P ...